At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Gimistotug +2 moredrug
Likely dose
Docetaxel 75 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Randomized, Multi-arm Study of BGB-A445 in Combination With Investigational Agents in Non-Small Cell Lung Cancer Patients Previously Treated With Anti-PD-(L)1 Antibody
In Brief
A Phase 2 clinical trial evaluating Gimistotug, Docetaxel, and 1 other intervention for Non-Small Cell Lung Cancer. Completed, enrolled 35 participants across 18 sites in 2 countries.
Detailed Summary
The main objective of this study was to evaluate the anti-tumor activity of gimistotug (BGB-A445) plus investigational agents in participants with non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina, South Korea
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedSep 2023
Enrollment StartOct 2023
Primary CompletionDec 2024
TodayJul 2026
First PostedSep 8, 2023
Enrollment StartOct 23, 2023
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.8 years ago
Interventions
Gimistotugdrug
Administered intravenously
Docetaxeldrug
75 milligrams per square meter (mg/m\^2) administered intravenously
BGB-15025drug
Administered orally